Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin
Authors' conclusion
Patients with higher LVMi at baseline experienced greater LVM regression with empagliflozin.
Study context
- Population
- Patients with T2D and coronary artery diseaseLVMi ≤ 60: n = 54
- Participants
- 97 patients
- Comparison
- Empagliflozin vs placebo, by baseline LVMi subgroup
- Primary endpoint
- Change in LV mass indexed to body surface area (LVMi), by baseline LVMi subgroup
- Follow-up
- 6 months
Methodological detailssub-analysis by baseline LVMi, placebo-controlled, ANCOVA with interaction term
- Sub-analysis by baseline LVMi
- Placebo-controlled
- ANCOVA with interaction term
Primary result
As reported in the abstract
LVMi regression, empagliflozin vs placebo, by baseline LVMi subgroup
Empagliflozin vs PlaceboAdjusted difference, g/m2 (95% CI)P value
Baseline LVMi ≤ 60 g/m² subgroup
- 0.46(−3.44 to 2.52)
P = 0.76Baseline LVMi > 60 g/m² subgroup
- 7.26(−11.40 to −3.12)
P = 0.0011- Interaction between LVMi subgroup and treatment
- P for interaction = 0.007
Further findings
Baseline LVMi by subgroup
Baseline LVMi and 6-month change in LV volumes and LVEF
- No significant association: LV end systolic volume-indexed
- P for interaction = 0.086
- No significant association: LV end diastolic volume-indexed
- P for interaction = 0.34
- No significant association: LV ejection fraction
- P for interaction = 0.15
Original publication
Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin. Cardiovasc Diabetol. Published 28 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →